Citius Oncology: Funding, Investors & Team (Oct 2026)
Citius Oncology is a biopharmaceutical company that develops and commercializes oncology therapies. The company specializes in targeted therapies for cancer treatment, with a focus on immune-based approaches. The company recently gained FDA approval for LYMPHIR™, a therapy for relapsed or refractory cutaneous T-cell lymphoma.
Citius Oncology has raised $25.0M across 1 funding round on record, the most recent an undisclosed round of $25.0M announced in May 2026.
That round is above the $4.9M median round size for Health Care companies tracked on FundedIQ over the last two years.
Citius Oncology Company Profile and Key Stats
Latest funding round on record: May 2026.
Citius Oncology Funding Rounds
Citius Oncology Founders and Leadership Team
Contact details for the Citius Oncology team: 1 has a LinkedIn profile.
Start 14-day free trial →Citius Oncology Funding Compared to Other Health Care Startups
Citius Oncology's latest round of $25.0M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Citius Oncology in Health Care and Cranford
Companies Similar to Citius Oncology
Using technology and the best professionals, Wally, a membership-based dental care service, offers proactive,…
PreciseDx is a unique Cancer Risk Stratification company that offers personalized risk information by…
General Medicine provides a convenient and straightforward way to access top-quality healthcare services with…
Forty million men in the US and over 500 million worldwide suffer from urinary obstruction related to benign…
SedMed provides medical devices that support safer toileting transfers and help prevent falls for individuals…
Aptatek is developing cutting edge technologies for portable disease management devices that will improve…
Flow Medical offers multi-function catheters to aid in the diagnosis and treatment of venous thromboembolic…
Light Wave Dental Management offers management services for high-quality dental offices in Virginia.…
For health care systems and payers focused on improving maternal outcomes and health equity, our product is a…
Tempo Therapeutics creates materials that are designed for regenerative medicine, with a focus on being…
Vibronix was established by Dr. Ji-Xin Cheng and Dr. Pu Wang at Purdue University with the goal of offering…
People with chronic diseases can live their best lives thanks to Vheda Health. We concentrate on three areas…
Citius Oncology Funding FAQs
What does Citius Oncology do?
Citius Oncology is a biopharmaceutical company that develops and commercializes oncology therapies. The company specializes in targeted therapies for cancer treatment, with a focus on immune-based approaches. The company recently gained FDA approval for LYMPHIR™, a therapy for relapsed or refractory cutaneous T-cell lymphoma.
How much funding has Citius Oncology raised?
Citius Oncology has raised $25.0M across 1 round on record. The most recent is an undisclosed round of $25.0M announced in May 2026.
When did Citius Oncology last raise funding?
Citius Oncology's most recent funding round on record is an undisclosed round of $25.0M, announced in May 2026.
Who founded Citius Oncology?
FundedIQ lists Leonard Mazur (Founder) at Citius Oncology.
Where is Citius Oncology headquartered?
Citius Oncology is based in Cranford, New Jersey, United States.
How many employees does Citius Oncology have?
Citius Oncology is in the 1-10 employee band.
How does Citius Oncology's funding compare to other Health Care startups?
Citius Oncology's latest round of $25.0M is above the $4.9M median round size for Health Care companies on FundedIQ across 3,659 tracked companies over the last two years.
About FundedIQ's Citius Oncology Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Citius Oncology is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.